US EditionPublished • loading... • Updated
As one door closes for Regeneron’s lymphoma bispecific, another reopens
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
As one door closes for Regeneron’s lymphoma bispecific, another reopens
ORLANDO — Regeneron is facing another twist in its roller-coaster ride to win US approval of its lymphoma treatment, odronextamab, after a series of regulatory and manufacturing hurdles. Earlier in 2025, the Tarrytown, NY, drugmaker said ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
